Extent of apoptosis in ovarian serous carcinoma: Relation to mitotic and proliferative indices, p53 expression, and survival

Journal of Clinical Pathology - Molecular Pathology

Volumn 50, Issue 5, 1997, Pages 242-246

  Mc Menamin, Máirín E ^a   O'Neill, Amanda J ^a   Gaffney, Eoin F ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Apoptosis; Cell proliferation; Mitosis; Ovarian serous carcinoma; p53

Indexed keywords

DNA FRAGMENT; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LABELING INDEX; MITOSIS INDEX; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 9844253901     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.50.5.242     Document Type: Article

References (45)

1. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metast Rev 1992;11:95-103.
2. Solary E, Dubrez L, Eymin B. The role of apoptosis in the pathogenesis and treatment of diseases. Eur Respir J 1996, 9:1293-305.
3. Staunton MJ, Gaffney EF. Tumour type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 1995;103:300-7.
4. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73: 2013-6.
5. Hoffman B, Liebermann DA. Molecular controls of apoptosis: differentiation growth arrest primary response genes, proto-oncogenes, and tumour suppressor genes as positive and negative modulators. Oncogene 1994;9:1807-12.
6. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329: 1550-9.
7. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
8. Partridge HE, Phillips JL, Menck HR. The National Cancer Data Base report on ovarian cancer treatment in United States hospitals. Cancer 1996;78:2236-46.
9. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obsiet Gynecol 1985;65:264-9.
10. Ozols RF, Garvin AJ, Costa J, Simon RM, Young RC. Advanced ovarian cancer. Correlation of histologic grade with response to therapy and survival. Cancer 1980;45:572-81.
11. Sorbe B, Frankendal BO, Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obsiet Gynecol 1982;59:576-82.
12. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, et al. Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 1992;65:40-4.
13. Foulkes WD, Ragoussis J, Stamp GWH, Allan GJ, Trowsdale J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 1993;67: 551-9.
14. Kiechle-Schwarz M, Bauknecht T, Wienker T, Walz L, Pfleiderer A. Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Cancer 1993;72: 2423-32.
15. Van Dam PA, Vergote IB, Lowe DG, Watson JV, Van Damme P, Van der Auwera J-C, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor in ovarian carcinoma. J Clin Pathol 1994;47:914-19.
16. Tashiro H, Miyazaki K, Okamura H, Iwai A, Fukumoto M. c-myc Overexpression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer 1992;50: 828-33.
17. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56: 2178-84.
18. Henriksen R, Wilander E, Öberg K. Expression and prognostic significance of bcl-2 in ovarian tumours. Br J Cancer 1995;72:1324-9.
19. Mc Manus DT, Yap EPH, Maxwell P, Russell SEH, Toner PG, McGee JO'D. p53 expression, mutation and allelic deletion in ovarian cancer. J Pathol 1994;174:159-68.
20. Mc Manus DT, Murphy M, Arthur K, Hamilton PW, Russell SEH, Toner PG. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma. J Pathol 1996;179:177-82.
21. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, et al. Mutant p53 protein Overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38.
22. Klemi P-J, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
23. O'Neill AJ, Staunton MJ, Gaffney EF. Apoptosis occurs independently of bcl-2 and p53 Overexpression in non-small cell lung carcinoma. Histopathalogy 1996;29:45-50.
24. Gaffney EF, O'Neill AJ, Staunton MJ. In situ end-labelling, light microscopic assessment and ultrastructure of apoptosis m lung carcinoma. J Clin Pathol 1995;48:1017-21.
25. Meyn RE, Stephens LC, Ang KK, Hunter NR, Brock WA, Milas L, et al. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 1993;64:583-91.
26. Hollowood K, Macartney JC. Reduced apoptotic cell death in follicular lymphoma. J Pathol 1991;163:337-42.
27. Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993;170:1-8.
28. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105:341-9.
29. Sasano H. In situ end-labelling and its applications to the study of endocrine disease: how can we study programmed cell death in surgical pathology materials? Endocr Pathol 1995;6:87-9.
30. Potten CS. What is an apoptotic index measuring? A commentary. Br J Cancer 1996;74:1743-8.
31. Levine EL, Renehan A, Gossiel R, Davidson SE, Roberts SA, Chadwick C, et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995;37:1-9.
32. Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S, et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 1993;142:755-63.
33. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994;25:797-801.
34. Todd D, Yang G, Brown RW, Cao J, D'Agati V, Thompson TS, et al. Apoptosis in renal cell carcinoma: detection by in situ end-labelling of fragmented DNA and correlation with other prognostic factors. Hum Pathol 1996;27:1012-17.
35. Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994;173:333-9.
36. Baserga R. Principles of molecular cell biology of cancer: the cell cycle. In: Devita VI Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and practice of oncology. 4th edn. Philadelphia: JB Lippincott, 1993:60-6.
37. Mc Gahon A, Bissonette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994;83:1179-87.
38. Clarke AR, Sphyris N, Harrison DJ. Apoptosis in vivo and in vitro: conflict or complementarity? Mol Med Today 1996;2: 189-91.
39. Hall PA, Meek D, Lane DP. p53 integrating the complexity [editorial]. J Pathol 1996;180:1-5.
40. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62.
41. Bracey TS, Miller JC, Preece A, Paraskeva C. γ-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995;10:2391-6.
42. Forrester K, Lupold SH, Ott VL, Chay CH, Band V, Wang XW, et al. Effects of p53 mutants on wild type p53-mediated transactivation are cell type dependent. Oncogene 1995;10;2103-11.
43. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metast Rev 1992;11:121-39.
44. Smets LA. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti-Cancer Drugs 1994;5:3-9.
45. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995;11:217-28.